Abstract
We described chemical inhibitors of Mos1 transposition. Some were already known to affect a related prokaryotic transposase (Tn5) or HIV-1 integrase, whereas the other were new compounds in this field. The new compounds were all organized around a bis-(heteroaryl)maleimides scaffold. Their mechanism of action depended on the chemical substitutions on the scaffold. The cross-activity, between HIV-1 integrase and Mos1 transposase, of the new group of inhibitors showed that Mos1 transposase could constitute an excellent surrogate HIV-1 inhibitor screen.
Keywords: Heterocyclic chemistry, maleimides, transposon inhibitor, HIV-1 integrase inhibitor, mariner inhibitor
Mini-Reviews in Medicinal Chemistry
Title: First Mariner Mos1 Transposase Inhibitors (Supplementary Data)
Volume: 9 Issue: 4
Author(s): N. Bouchet, J. Bischerour, S. Germon, J. Guillard, M. Dubernet, M. C. Viaud-Massuard, O. Delelis, V. Ryabinin, Y. Bigot and C. Auge-Gouillou
Affiliation:
Keywords: Heterocyclic chemistry, maleimides, transposon inhibitor, HIV-1 integrase inhibitor, mariner inhibitor
Abstract: We described chemical inhibitors of Mos1 transposition. Some were already known to affect a related prokaryotic transposase (Tn5) or HIV-1 integrase, whereas the other were new compounds in this field. The new compounds were all organized around a bis-(heteroaryl)maleimides scaffold. Their mechanism of action depended on the chemical substitutions on the scaffold. The cross-activity, between HIV-1 integrase and Mos1 transposase, of the new group of inhibitors showed that Mos1 transposase could constitute an excellent surrogate HIV-1 inhibitor screen.
Export Options
About this article
Cite this article as:
Bouchet N., Bischerour J., Germon S., Guillard J., Dubernet M., Viaud-Massuard C. M., Delelis O., Ryabinin V., Bigot Y. and Auge-Gouillou C., First Mariner Mos1 Transposase Inhibitors (Supplementary Data), Mini-Reviews in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/138955709787847912
DOI https://dx.doi.org/10.2174/138955709787847912 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets CycloSal-Pronucleotides of Brivudine Monophosphate - Highly Active Antiviral Agents
Current Medicinal Chemistry - Anti-Infective Agents It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design The Role of CD8+ T Cell Soluble Factors in Human Immunodeficiency Virus Infection
Current Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry